Compare IH & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | ENTX |
|---|---|---|
| Founded | 1996 | 2010 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.5M | 58.2M |
| IPO Year | 2020 | 2015 |
| Metric | IH | ENTX |
|---|---|---|
| Price | $1.42 | $1.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 5.4K | ★ 2.9M |
| Earning Date | 03-31-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $42,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $7.30 | $23.14 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $0.91 |
| 52 Week High | $3.60 | $3.22 |
| Indicator | IH | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 46.17 | 58.70 |
| Support Level | N/A | $1.45 |
| Resistance Level | $1.53 | $1.85 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 31.27 | 47.12 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources. All of the groups revenue is generated from Chinese Mainland.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.